What is Bioventus's D&A?

Bioventus (BVS) reported D&A of $1.11M in Q1 2026.

How has Bioventus's D&A changed year-over-year?

Bioventus's D&A decreased by 30.5% year-over-year, from $1.59M to $1.11M.

What is the long-term trend for Bioventus's D&A?

Over 4 years (2021 to 2025), Bioventus's D&A has grown at a -9.0% compound annual growth rate (CAGR), from $8.36M to $5.73M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Bioventus BVS D&A

D&A at other companies

Zimmer Biomet HoldingsZBH

$162.1M+7.4%

MedtronicMDT

$716M-14.8%

Globus MedicalGMED

$29.53M-55.3%

ArtivionAORT

$6.34M+16.4%

EnovisENOV

$41.9M+0.2%

Avanos MedicalAVNS

$10.2M+6.3%

Other financials

Income statement

See full

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Balance sheet

See full

Cash & equivalents$35.8M+57.2%

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Cash flow

See full

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Valuation

See full

Market cap$659.19M+51.7%

Enterprise value$911.76M+17.2%

P/E23.1×—

P/S1.1×+0.4×

Profitability

See full

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Returns & leverage

See full

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bioventus's D&A?: Bioventus (BVS) reported D&A of $1.11M in Q1 2026.
How has Bioventus's D&A changed year-over-year?: Bioventus's D&A decreased by 30.5% year-over-year, from $1.59M to $1.11M.
What is the long-term trend for Bioventus's D&A?: Over 4 years (2021 to 2025), Bioventus's D&A has grown at a -9.0% compound annual growth rate (CAGR), from $8.36M to $5.73M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.